alexa Anti-tumor And Immunomodulatory Effects Of Cordyceps Militaris Polysaccharide Fraction
ISSN: 2471-9552

Immunotherapy: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Tumor & Cancer Immunology and Immunotherapy
July 17-18, 2017 Chicago, USA

Liyan Song, Sixue BI and Rongmin YU
Jinan University, Chinat
Posters & Accepted Abstracts: Immunotherapy (Los Angel)
DOI: 10.4172/2471-9552-C1-006
Statement of the problem: Although standard therapeutic protocols for cancer have been improved, it is still imperative to investigate novel anti-tumor strategies for eliminating cancer cells with little toxicity to normal cells. It is generally accepted that natural polysaccharides are capable of immunomodulatory activities. As a traditional Chinese medicine, Cordyceps militaris is widely used for health supplement. This study aims to investigate the anti-tumor and immunomodulatory effects of Cordyceps militaris polysaccharide fraction (CMPF). Methodology & Theoretical Orientation: The mouse model of S180 sarcoma was established and the effect of CMPF on tumor weight, organ index, and cytokines were examined in S180-bearing mice. The effect of CMPF on carbon clearance ability and DTH reaction of immunosuppressive mice were also investigated. Additionally, the immunomodulatory effect of CMPF and the possible mechanism were studied in macrophages and splenic lymphocytes. Findings: CMPF had no effect on proliferation of S180 cells in vitro. However, it inhibited tumor growth, increased levels of cytokines TNF-alpha and IL-2, and improved spleen and thymus indexes in S180-bearing mice. When combined with 5-fluorouracil, CMPF exerted synergistic effect and reduced toxicity of 5-fluorouracil. Other in vivo experiment results showed that CMPF enhanced carbon clearance ability and DTH reaction of immunosuppressive mice. On the other hand, in vitro assays revealed that CMPF promoted proliferation of splenic lymphocytes and cytotoxicity of NK cells to YAC-1 cells. CMPF also increased secretion of IL-2, development of cell cycle toward S phase, as well as T cell subpopulation. The phagocytosis function of macrophages and secretion of both NO and TNF-alpha by macrophages were also promoted by CMPF. Conclusion & Significance: These results indicate that CMPF possesses immunomodulatory effect on multiple immune cells in vitro. CMPF exhibited anti-tumor effect in vivo probably via immunomodulation. CMPF could potentially be used as a functional supplement candidate for tumor therapy.

Dr. Liyan Song is currently a Professor of Pharmacology in Biotechnological Institute of Chinese Materia Medica, Jinan University, China. She has worked with cancer and immunology studies in the past years. Specially, she is interested in mechanism research involved in cell signaling pathways. Her research team is also engaged in the development of novel antitumor drug, and financially supported by several foundations including Major National Science and Technology Projects/ Significant New Drugs Creation as well as National Natural Science Foundation of China.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version